For example, ripretinib targets KIT, PDGFRα/β, kinase insert domain receptor (KDR), and colony‐stimulating factor 1 receptor (CSF1R alias C‐FMS) and has been developed to overcome the TKI resistance occurring in GIST patients. Here, KDR is linked to gastrointestinal stromal tumor.